Clinical Trials Logo

Pancreatic Ductal Carcinoma clinical trials

View clinical trials related to Pancreatic Ductal Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06182072 Recruiting - Clinical trials for Pancreatic Ductal Carcinoma

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Start date: September 14, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine and nab paclitaxel (G-nP) in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)

NCT ID: NCT05293496 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Start date: April 19, 2022
Phase: Phase 1
Study type: Interventional

Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled. Vobramitamab duocarmazine and lorigerlimab are administered separately on Day 1 of every 4-week (28-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to 2 years. Tumor assessments are performed every 8 weeks (± 7 days) for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD). Participants will be followed for safety throughout the study. .

NCT ID: NCT05288205 Recruiting - Colorectal Cancer Clinical Trials

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Start date: April 14, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.

NCT ID: NCT04121286 Recruiting - Breast Cancer Clinical Trials

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Start date: June 10, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.

NCT ID: NCT04045496 Recruiting - Breast Cancer Clinical Trials

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

Start date: September 26, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.

NCT ID: NCT02243007 Recruiting - Clinical trials for Resectable Pancreatic Cancer

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Start date: September 2014
Phase: Phase 2
Study type: Interventional

This research study is a Phase II clinical trial, which evaluates a combination of drugs, FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, in the management of participants with resectable pancreatic cancer prior to surgery.